GSK

Stock Details

GSK is GSK plc's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 35.00$. Average daily volumn in 3 months 5.27M. Market cap 71.85B

Stock symbol : GSK. Exchange : NYSE. Currency : USD
Lastest price : 35.10$. Total volume : 330.30k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

GSK plc (GSK)

Last Price

35.10$

Change

-0.02

Volume

330.30k


Previous Close	35.12
Open	35.56
Day Range	35.10-35.42
Bid	35.44 x 1.8k
Ask	35.46 x 1.1k
Volume	330.3k
Average Volume	5.27M


Market Cap	71.85B
Beta	0.29
52 Week Range	28.47-46.97
Trailing P/E	12.95
Foward P/E	9.72
Dividend (Yield %)	5.37%
Ex-Dividend Date	2022-11-17

Financial Details

According to GSK plc's financial reports the company's revenue in 2021 were 34.11B an decrease(0%) over the years 2020 revenue that were of 34.1B. In 2021 the company's total earnings were 4.38B while total earnings in 2020 were 5.75B(-20%).

Loading ...

Organization

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory... , HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Wave Life Sciences Ltd.; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Market Cap:

71.85B

Revenue:

34.11B

Total Assets:

79.1B

Total Cash:

4.27B

News about "GSK plc"

GSK's Earnings Expected to Grow in 4Q Despite Sales Dip -- Earnings Preview

Source from : MarketWatch - 13 hours ago

GSK PLC is scheduled to report results for the fourth quarter on Feb 1. Here's what you need to know: SALES FORECAST: Sales at the British pharma major are expected to be 7.07 billion pounds ($8.73 ...See details»

How Do Things Look For GSK plc (NYSE: GSK) In The Short-Term?

Source from : stocksregister - 1 days ago

GSK plc (NYSE:GSK) price is hovering higher on Monday, January 30, jumping 0.25% above its previous close. A look at today’s price movement shows that the recent level at last check reads $35.30, with ...See details»

BRIEF-Gsk PLC Reports 10.95% Passive Stake In Wave Life Sciences Ltd

Source from : Reuters - 1 days ago

GSK PLC REPORTS 10.95% PASSIVE STAKE IN WAVE LIFE SCIENCES LTD. AS OF JANUARY 23, 2023 - SEC FILING Further company coverage: ...See details»

GSK plc (GSK) and the Battle of Fundamentals vs. Technicals

Source from : newsheater - 6 month ago

GSK plc (NYSE:GSK) went down by -0.06% from its latest closing price compared to the recent 1-year high of $47.82. The company’s stock price has collected -0.06% of loss in the last five trading ...See details»

Does GSK plc (NYSE: GSK) Still Need To Convince Analysts?

Source from : stocksregister - 6 days ago

GSK plc (NYSE:GSK) traded at $34.70 at close of the session on Tuesday, 01/24/23, made a downward move of -1.87% on its previous day’s price. Looking at the stock we see that its previous close was ...See details»

GSK financials should look good but clinic is the focus

Source from : Proactiveinvestors - 4 days ago

GSK PLC (LSE:GSK, NYSE:GSK) has done well enough since the Haleon consumer products arm was spun out last year, though after a decent run-up to the end of 2022, shares have gone a bit flat since.See details»

GSK falls Tuesday, underperforms market

Source from : MarketWatch - 7 days ago

Shares of GSK PLC dropped 1.69% to £13.87 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 ...See details»

GSK's New Drugs and Pipeline Hold the Key to Growth in 2023

Source from : Nasdaq - 28 days ago

The company changed its name to GSK plc from GlaxoSmithKline plc in mid-May 2022. In July 2022, GSK de-merged its Consumer Healthcare (CHC) segment into a standalone company. The independent ...See details»

GSK plc (GSK) Reveals an Earnings Mystery

Source from : newsheater - 6 month ago

GSK plc (NYSE:GSK) went down by -1.04% from its latest closing price compared to the recent 1-year high of $47.82. The company’s stock price has collected 1.30% of gains in the last five trading ...See details»

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca

Source from : Yahoo News - 1 month ago

GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.' Luke ...See details»

GSK plc: Reaffirming BUY as company advances pipeline

Source from : Yahoo Finance - 22 days ago

GlaxoSmithKline, based in London, is a global healthcare company engaged in the discovery, development, manufacture and marketing of pharmaceutical products. The company's leading products include ...See details»

GSK plc (GSK) Presents at 41st Annual JPMorgan Healthcare Conference (Transcript)

Source from : Seeking Alpha - 21 days ago

I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the GSK presentation. You're going to hear from GSK, CEO, Emma Walmsley, and we can ...See details»

GSK growing optimistic on HIV but long term challenges remain - analyst

Source from : Proactiveinvestors - 18 days ago

GSK shows increasing confidence in new HIV treatments but longer term challenges remain, according to Jefferies GSK PLC (LSE:GSK, NYSE:GSK) is growing at a "robust" rate and showing increasing ...See details»

GlaxoSmithKline plc

Source from : Fortune - 3 years ago

America

Europe

Asia

Others

GSK